Literature DB >> 8261816

Effect of lidocaine on in vivo hepatic function.

B Mets1, R Hickman, U Neveling, M Emms, D O Chalton.   

Abstract

Lidocaine is administered to assess donor or recipient liver function during hepatic transplantation. This study was performed to determine whether lidocaine administered at a constant concentration affected hepatic function or had demonstrable effects on hepatocellular ultrastructure. Fourteen pigs were randomly allocated to receive either a two-stage infusion of lidocaine hydrochloride or of saline. Transhepatic blood samples were taken and ultrasonic portal venous and hepatic arterial blood flow readings made on animals anesthetized with isoflurane in nitrous oxide. Liver biopsies were taken for histological analysis and determination of adenine nucleotide status prior to and after 2 hr of the two-stage infusion. A mean systemic constant plasma lidocaine concentration of 5.9 micrograms/ml was achieved during the second hour of infusion. There were no differences between the two groups in a large number of indices of hepatic function and plasma composition prior to and during the second hour of the respective infusions. Hepatic blood flow was also similar at these times. On histological examination there were no electron microscopic changes that could be specifically attributed to the administration of lidocaine. However, there were progressive changes with time. This study suggests that in anesthetized pigs a constant lidocaine concentration of about 6 micrograms/ml has no detrimental effect on hepatic function. Progressive hepatic ultrastructural changes occurred that could not be attributed to the administration of lidocaine. These may be the result of anesthetic administered or the surgery performed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8261816     DOI: 10.1007/bf01299890

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  20 in total

1.  Comparison of toxicity of intravenously given local anesthetic agents in man.

Authors:  F F FOLDES; R MOLLOY; P G McNALL; L R KOUKAL
Journal:  J Am Med Assoc       Date:  1960-04-02

2.  A comparative study of the effects of procaine, lidocaine, tetracaine and dibucaine on the functions and ultrastructure of isolated rat liver mitochondria.

Authors:  C Tarba; C Crăcium
Journal:  Biochim Biophys Acta       Date:  1990-08-09

3.  Functional state of the donor liver and early outcome of transplantation.

Authors:  M Oellerich; M Burdelski; B Ringe; C Wittekind; P Lamesch; H U Lautz; G Gubernatis; R Beyrau; R Pichlmayr
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

4.  Uncoupling effects of local anesthetics on rat liver mitochondria.

Authors:  P Dabadie; P Bendriss; P Erny; J P Mazat
Journal:  FEBS Lett       Date:  1987-12-21       Impact factor: 4.124

5.  Perfusion of the isolated pig liver. Functional assessment under control normothermic conditions.

Authors:  R Hickman; S J Saunders; E Simson; J Terblanche
Journal:  Br J Surg       Date:  1971-01       Impact factor: 6.939

Review 6.  General anesthesia and hepatic circulation.

Authors:  S Gelman
Journal:  Can J Physiol Pharmacol       Date:  1987-08       Impact factor: 2.273

7.  Evaluation of quantitative liver function tests in liver donors.

Authors:  M Burdelski; M Oellerich; P Lamesch; E Raude; B Ringe; P Neuhaus; S Bortfeld; C Kämmerling; H Raith; M Scheruhn
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

8.  Drugs as indicators of hepatic function.

Authors:  R A Branch
Journal:  Hepatology       Date:  1982 Jan-Feb       Impact factor: 17.425

9.  Lidocaine disposition kinetics in monkey and man. I. Prediction by a perfusion model.

Authors:  N Benowitz; F P Forsyth; K L Melmon; M Rowland
Journal:  Clin Pharmacol Ther       Date:  1974-07       Impact factor: 6.875

10.  Heart failure and hepatitis in a patient taking tocainide.

Authors:  I L Nauta; C M Ruland; D H Hertzberger; J B Rensing
Journal:  Int J Cardiol       Date:  1984-01       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.